First-Line Nab-Paclitaxel Is Superior To Docetaxel For Metastatic Breast Cancer

[News]

CHICAGO, May 26, 2009 - New data show that nab-paclitaxel (AbraxaneR for Injectable Suspension) prolongs investigator-assessed, median progression-free survival (PFS) by almost seven months versus the highest standard dose of docetaxel in women with metastatic breast cancer. Nab-paclitaxel is a novel albumin-bound paclitaxel, an established chemotherapy agent, combined with albumin, a very small naturally-occurring protein.

More... (http://www.medicalnewstoday.com/articles/151550.php)